Germany · Delayed Price · Currency is EUR Lytix Biopharma AS Statistics
Total Valuation
FRA:6BG has a market cap or net worth of EUR 60.69 million. The enterprise value is 53.24 million.
| Market Cap | 60.69M |
| Enterprise Value | 53.24M |
Important Dates
The next estimated earnings date is Thursday, February 12, 2026.
| Earnings Date | Feb 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 75.09M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 2.99% |
| Owned by Institutions (%) | 12.19% |
| Float | 38.58M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1,886.58 |
| PB Ratio | 9.07 |
| P/TBV Ratio | 9.07 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -8.52 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.99, with a Debt / Equity ratio of 0.03.
| Current Ratio | 5.99 |
| Quick Ratio | 5.99 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -322.60 |
Financial Efficiency
Return on equity (ROE) is -127.06% and return on invested capital (ROIC) is -78.30%.
| Return on Equity (ROE) | -127.06% |
| Return on Assets (ROA) | -62.19% |
| Return on Invested Capital (ROIC) | -78.30% |
| Return on Capital Employed (ROCE) | -94.47% |
| Revenue Per Employee | 4,021 |
| Profits Per Employee | -781,121 |
| Employee Count | 7 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +73.78% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +73.78% |
| 50-Day Moving Average | 0.80 |
| 200-Day Moving Average | 0.67 |
| Relative Strength Index (RSI) | 44.36 |
| Average Volume (20 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, FRA:6BG had revenue of EUR 32,170 and -6.25 million in losses. Loss per share was -0.09.
| Revenue | 32,170 |
| Gross Profit | 32,170 |
| Operating Income | -6.44M |
| Pretax Income | -6.25M |
| Net Income | -6.25M |
| EBITDA | -6.44M |
| EBIT | -6.44M |
| Loss Per Share | -0.09 |
Balance Sheet
The company has 7.68 million in cash and 207,443 in debt, with a net cash position of 7.47 million.
| Cash & Cash Equivalents | 7.68M |
| Total Debt | 207,443 |
| Net Cash | 7.47M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 6.69M |
| Book Value Per Share | 0.10 |
| Working Capital | 6.62M |
Cash Flow
| Operating Cash Flow | -4.88M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -20,024.04% |
| Pretax Margin | -19,424.83% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FRA:6BG does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -10.30% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |